Drug Profile
Pemlimogene merolisbac - Chinook Therapeutics/Jannsen Biotech
Alternative Names: ADU 214; JNJ-64041757; JNJ-757Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Aduro BioTech
- Developer Bristol-Myers Squibb; Chinook Therapeutics; Janssen
- Class Cancer vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Epidermal growth factor inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 05 Mar 2021 No development reported - Phase-I/II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Belgium, USA (IV)
- 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics